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Abstract Sepsis, a widely prevalent disease with increasing
morbidity and mortality, is thought to result from uncontrolled
in£ammatory responses to microbial infection and/or compo-
nents. However, failure of several experimental anti-in£amma-
tory therapies has necessitated re-evaluation of the paradigm
underlying the pathogenesis of this complex disorder. Apoptotic
cell death forms a second dominant feature of septic shock in
patients and animal models. Anti-apoptotic strategies may pro-
tect animals from septic death. However, simultaneous occur-
rence of apoptosis and in£ammation is necessary for septic
death. At the cellular level, apoptosis plays a central role in
the development of the lymphoid system and regulation of im-
mune responses. Immune activation renders cells refractory to
apoptosis while apoptosis of activated lymphocytes is an impor-
tant immunoregulatory mechanism. Factors such as complement
factor 5a, caspase-1 and mitogen-activated protein kinase,
which participate in apoptosis as well as pro-in£ammatory path-
ways, may be responsible for simultaneous activation of apopto-
sis and in£ammation in sepsis. Further identi¢cation of other
similar biochemical events capable of co-activating in£ammation
and apoptosis may provide new targets for therapy of this hith-
erto untreatable disease.
% 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Sepsis results from dysregulation of the normally protective
anti-microbial host defense mechanisms, and is characterized
by a systemic in£ammatory response manifested by fever,
mental confusion, hypotension, coagulopathy, cell and mul-
ti-organ injury [1,2]. Sepsis remains a major cause of morbid-
ity and mortality in the intensive care unit. Its incidence in the
USA is approximately three cases per 1000 population, out of
which nearly 50% die due to a more severe form of disease
called septic shock. The fact that activated protein C alone,
from the range of experimental anti-in£ammatory therapies
developed to treat sepsis (Table 1) was approved, albeit for
restricted use, for treatment of sepsis, emphasizes the continu-
ing necessity to understand the patho-physiological mecha-
nism(s) underlying this complex disorder.
Recent studies have shown an increased incidence of apo-
ptosis during septic shock. Hotchkiss et al. [3] reported exten-
sive apoptosis of T and B lymphocytes in sepsis patients. Ap-
optotic lymphocyte death can cause impairment of immune
responses [4,5] and anergy and predispose patients to septic
death [6]. Increased apoptosis is also observed in animal mod-
els of sepsis and its inhibition protects animals from lethality
[7^10]. However, the exact relevance of cell death to the
pathogenesis of septic shock is poorly understood. Here, we
identify apoptosis and in£ammation as dual pathogenic fac-
tors involved in various animal models of septic shock and
hypothesize that simultaneous activation of these two process-
es may represent a critical pathogenic step in septic shock.
Identi¢cation of condition(s) co-activating these processes
may provide useful therapeutic targets for sepsis.
2. In£ammation and apoptosis in animal models of sepsis
Research in sepsis has relied heavily on a number of animal
models such as bacterial endotoxin (lipopolysaccharide, LPS)-
induced mortality, D-galactosamine+LPS-induced lethality
(DGL), cecal ligation and puncture (CLP) [11^17] and colon
ascendent stent peritonitis (CASP) [18]. While LPS- and
DGL-induced lethality models are more popular, CLP is con-
sidered clinically the more relevant model of septic shock. All
these models exhibit little similarity and di¡er with respect to
the cytokines involved in development of sepsis (Table 2).
Systemic in£ammation is a common feature of all these
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Table 1
Experimental therapies for sepsis
Target Therapy
Bacterial endotoxin Endotoxin neutralizing antibodies
TNFK, IL-1 Cytokine neutralizing agents
PAF, thromboxane synthase PAF antagonists, ketoconazole
Reactive oxygen species N-Acetylcysteine
NO scavenger/iNOS inhibitor PHP, L-NAME
Immune modulation Glucocorticoids, pentoxifylline,
IFNQ, G-CSF
Coagulation pathway Factor IXa, Xa, XIa, XIIa, TFPI
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animal models. Various proin£ammatory cytokines including
tumor necrosis factor-K (TNFK), interleukin (IL) 6, interfer-
on-Q (IFNQ), IL-1L, and IL-18 [19^21] are overexpressed dur-
ing sepsis and their inhibition suppresses the pathological re-
sponse and protects animals from septic death (Table 2). For
instance, TNFK depletion by either pharmacological strategies
or genetic disruption signi¢cantly improves animal survival
after endotoxin challenge [22,23]. Similarly, inhibition of ac-
tivities of several other pathogenically relevant cytokines in-
cluding IL-1L [24,25], IFNQ [26^28], IL-6 [29], transforming
growth factor-L (TGF-L) [30] and high mobility group 1
(HMG-1) protein [31,32] (Table 2) protects animals from sep-
sis [33^35]. In addition, protective e¡ects of endogenous anti-
in£ammatory phospholipids have also been reported [36].
However, evidence suggests that unlike the traditionally held
view, the in£ammatory milieu in septic animals and individu-
als is more complex. Septic patients also exhibit features con-
sistent with immunosuppression and high levels of anti-in-
£ammatory cytokines such as IL-4 or IL-10. Reversal of
this Th2 response [37] and immunostimulation using granulo-
cyte colony-stimulating factor (G-CSF) [38], which increases
neutrophils and IFNQ, a potent macrophage activator that
restores HLA-DR expression and TNFK production [39],
have shown bene¢cial results. However, excessive elimination
of cytokines can be harmful, e.g. co-neutralization of TNFK
and IL-1L enhanced rather than reduced mortality in a neu-
tropenic rat model of sepsis while IL-18 gene deletion en-
hanced LPS-induced mortality of Propionibacterium acnes-
treated mice [40]. Cytokines therefore have protective and
pathogenic roles in septic death and their optimal levels
(and activity) are necessary for survival of septic animals [21].
Apoptosis is a second prominent feature of sepsis. Increased
apoptosis is observed in all these models of sepsis. LPS in-
duces apoptosis in glomerular [41], heart [42] and other cells.
Co-administration of D-galactosamine and LPS is associated
with liver damage through apoptosis [43]. CLP leads to apo-
ptosis in thymus, spleen, lung, and gut [44] while CASP causes
bone marrow apoptosis [18] and inhibition of apoptosis was
shown to protect animals from lethal shock (see below). Thus,
like in£ammation, apoptosis forms an important feature of all
above models of septic shock.
Apoptosis is a mechanism of controlled disassembly of cells
brought about by activation of certain specialized proteases
called caspases (cas). Inhibitors of cas-1 and cas-3 protect
mice from death induced by LPS [7,8,20], DGL [9] and
CLP [10] and rats from LPS-induced lethality [7]. Since cas-
1 and cas-3 also mediate proteolytic maturation of cytokines
IL-1L and IL-18 [45] and IL-18 and IL-16 [46] respectively,
the protective e¡ect of caspase inhibition could be a result of
inhibition of cytokine maturation.
If apoptosis is really central to sepsis, other anti-apoptotic
strategies, which are devoid of anti-in£ammatory activity,
should also protect animals from septic shock. Indeed, trans-
genic expression of the anti-apoptotic protein Bcl-2 and hepa-
tocyte growth factor-induced Bcl-2 expression protect mice
from LPS-induced hepatic failure and DGL- [43] and CLP-
induced death [10] respectively.
Clearly, apoptosis is a necessary pathogenetic factor and its
inhibition may be a useful therapeutic strategy for sepsis [6].
In agreement, treatment with agents like gadolinium chloride
[47], depletion of glutamyl-cysteinyl-glycine [48], complement
factor C5a blockade [49] and N-acetylcysteine (Joshi and
Cross, unpublished observations) which prevent apoptosis,
albeit indirectly, can protect from sepsis.
3. Apoptosis and in£ammation
Apoptosis plays a central role in the generation of the lym-
phoid system. Developing lymphocytes are destined to die
unless a functional antigen receptor is produced through
gene rearrangements to trigger a rescue signal. Lymphocytes
bearing ‘self-reactive’ receptors are eliminated by apoptosis to
Table 2
Neutralizing various cytokines protects animals from lethality
Cytokine/chemokine Animal model Reference
IL-1 LPS-induced lethality in mice [24,25]
IL-6 LPS-induced lethality in mice [29]
IFNQ LPS-induced lethality, CLP, murine Gram-negative sepsis [26^28]
IL-12 LPS-induced lethality in mice, Schwarzman reaction [83]
IL-18 Propionibacterium acnes/LPS-induced lethality, LPS-induced lethality [21,84]
TNFK Escherichia coli-induced death in mice and baboons [22^24]
MIP1K Murine endotoxemia, CLP [85,86]
HMGB-1 LPS-induced lethality in mice [87]
MIF TSST-1-induced shock [33^35]
C5a LPS-induced lethality in rats [49,80]
Fig. 1. Simultaneous activation of apoptosis and pro-in£ammatory
events may precipitate septic death. Apoptosis of antigen non-reac-
tive cells and activated cells plays a central role in stimulation and
downregulation of the immune response. Simultaneous activation of
pro-in£ammatory and apoptotic events can cut short the immune
response, disrupt immunoregulatory networks and precipitate septic
death.
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protect the organism from inappropriate assault. Similarly,
mitogenic activation of neutrophils and monocytes inhibits
the naturally active apoptotic pathways in these cells, through
upregulation of Bcl-2 family member genes like B£-1 [50^52].
Immunostimulation activates the transcription factor NF-UB
which mediates expression of TRAF-1, TRAF-2, cIAP-1 and
cIAP-2 genes that block the activation of cas-8, a key initiator
of apoptosis, and inhibit apoptosis [53]. The enhanced surviv-
al of the in£ammatory cells helps in ampli¢cation and suste-
nance of in£ammatory responses. On the other hand, upreg-
ulation of apoptosis-inducing gene products like Cardinal [54],
the death receptor Fas and the Bcl-2 family protein Bim stim-
ulates the death of activated lymphocytes through activation-
induced death pathways, leading to downregulation of on-
going immune responses [55,56]. Thus apoptosis is involved
in a constant interplay with the in£ammatory system that is
critical to the development and homeostasis of immune re-
sponses [55,56] and its premature induction concomitantly
with in£ammation may cut short the immune response, dis-
rupt the immunoregulatory processes and lead to septic death
(Fig. 1).
4. Sepsis-related lethality is dependent upon dual activation of
apoptosis and in£ammation
Although important, neither apoptosis nor in£ammation
alone is su⁄cient for lethality in animal models. Apoptotic
hepatocyte death due to inhibition of RNA synthesis caused
by D-galactosamine-induced reduction of hepatocyte UTP lev-
els [43] sensitizes mice to LPS-induced lethality [57]. Inhibition
of this hepatocyte apoptosis by treatment with exogenous ur-
idine or UTP protects mice from DGL-induced lethality [57]
indicating the importance of apoptosis as a necessary patho-
genetic factor for DGL-induced lethality. Similarly, apoptosis
resulting from inhibition of RNA synthesis by agents like
actinomycin D and K-amanitine also renders mice hypersensi-
tive to LPS-induced death [58]. Thus, apoptosis appears to be
a necessary sensitizing step for endotoxin-induced lethality in
mice.
Apoptosis has to be complemented by immunoreactivity to
bacterial components for septic death. Freudenberg et al. [59]
demonstrated that C3H/HeJ mice, which lack the functional
receptor of LPS called TLR-4, are resistant to DGL-induced
death. TLR-4 belongs to a family of 10 Toll-like receptors
(TLR) which recognize di¡erent pathogen-associated molecu-
lar patterns and stimulate anti-microbial innate immune re-
sponses. And the absence of TLR-4 renders animals resistant
to death in response to CLP [60], CASP [61] and endotoxe-
mia.
Therefore extrapolating from the ¢ndings in the DGL mod-
el, the protective e¡ect of caspase inhibition and the impor-
tance of apoptosis and in£ammation in di¡erent models of
sepsis, we hypothesize that simultaneous activation of apopto-
tic cell death and in£ammation is essential for pathogenesis of
septic shock. Simultaneous activation of pro-in£ammatory
processes and apoptosis may disrupt the normal immuno-
regulatory mechanism(s) and make the host susceptible to
septic death (Fig. 1).
This hypothesis of synergistic lethality may also be sup-
ported by an earlier observation that superantigens such as
staphylococcal enterotoxin B and toxic shock syndrome toxin
1 (TSST-1), which are e⁄cient inducers of apoptosis of T and
B cells [62,63], induce LPS hypersensitivity. For instance, pre-
treatment with TSST-1 renders rabbits 50 000-fold more sus-
ceptible to LPS-induced lethality [64]. This requirement of two
signals for induction of septic shock-dependent death is
summed up in the ‘two-hit’ hypothesis by Bannan and co-
workers [66]. They explain the synergism between Gram-neg-
ative bacterial LPS and Gram-positive bacterial superantigen
to produce lethal shock [65] in terms of a necessity for two
episodes of infection ^ one with Gram-negative bacteria and
the other with Gram-positive bacteria, for pathogenesis of
sepsis [66]. Our hypothesis may provide a possible molecular
mechanism underlying this two-hit hypothesis.
5. Simultaneous activation of cell death and in£ammation in
sepsis
Several mechanisms may be involved in simultaneous acti-
vation of apoptosis and in£ammatory processes in sepsis. Pro-
teins participating in biochemical pathways shared by in£am-
mation as well as apoptosis may be responsible. For instance,
we have shown that overexpression and activation, during
lethal response to LPS, of cas-1, which is an important medi-
ator of apoptosis and proteolytic maturation of cytokines IL-
1 and IL-18 [39,40], leads to endotoxic shock and its inhibi-
tion protects mice from death [20]. Similarly, cas-3, which
mediates cell death [67] and maturation of IL-18 and IL-16
[46], may also be responsible for triggering the pathological
events in septic shock. We have also shown that during pro-
tective immune responses to LPS, type I interferons (IFNK/L)
play an important IL-1-regulatory role which is disturbed
during lethal endotoxemia (Joshi et al., manuscript submit-
ted). IFNK/L-induced signaling molecules like dsRNA-depen-
dent protein kinase, which mediate NF-UB activation and
MHC gene expression along with caspase-dependent cell
death, may be important to septic death [68]. Another protein
called p38 mitogen-activated protein (MAP) kinase plays an
important role in synthesis of cytokines like TNFK and IL-1L
and its inhibitors are anticipated to provide useful therapies
for treatment of in£ammatory disorders. MAP kinase path-
ways consist of sequential phosphorylation and activation of a
three-kinase cascade: MEKK-MEK-MAPK, and are also in-
volved in di¡erential regulation of apoptosis and survival in
thymocytes. This dual e¡ect of MAP kinases is mediated by
two proteins, ERK1 [69,70] and p38 [71,72], which regulate
T cell receptor-induced multiplication and apoptosis respec-
tively. The simultaneous activation of these two kinases may
lead to co-activation of cell replication and apoptosis. Recent
studies have shown that transient activation of extracellular
signal-regulated kinases (ERKs) stimulates multiplication,
while their sustained activation promotes cell cycle arrest in
multiple cell types and death [73]. The systemic in£ammatory
reaction associated with septic shock may also lead to a sus-
tained activation of ERKs which in turn may cause cell cycle
arrest of immune cells and lead to apoptotic death. Secondly,
improved e⁄cacy of host anti-microbial responses stimulated
by presentation of microbial peptides scavenged by dendritic
cells from apoptotic infected macrophages [74] can dictate co-
existence of in£ammatory and apoptotic processes. Thirdly,
macrophages which are responsible for phagocytosis and elim-
ination of apoptotic cells exhibit enhanced responses [75] or
express anti-in£ammatory cytokines like TGF-L [76]. Irrespec-
tive of the underlying mechanism, the deleterious e¡ects of
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simultaneous activation of apoptosis and in£ammation have
been exploited e¡ectively by microbes like Shigella £exneri
[77] and myxoma virus [78].
Thus, multiple mechanisms may be responsible for the si-
multaneous activation of apoptosis and in£ammation and
identi¢cation of the responsible factors may help design useful
therapies for sepsis. For example, complement factor 5a
(C5a), which is critical for lethality in CLP, stimulates the
expression of the pro-in£ammatory cytokines IL-6 [79] and
TNFK [79,80] as well as thymocyte apoptosis through activa-
tion of cas-3, -6, and -8 [81] and its blockade protects mice
from CLP-induced mortality [49]. On the other hand, this
hypothesis may also explain the failure of TNFK-neutralizing
therapies in the treatment of septic shock [82]. Interaction of
TNFK, a pro-in£ammatory pathogenic cytokine in septic
shock, with its receptor (TNF-R1) induces recruitment of
the death domain-containing cytosolic adapter proteins
TRADD (TNF-R1-associated death domain) and FADD
(Fas-associated domain), and procaspase-8, which triggers
the caspase activation cascade and apoptosis. However, NF-
UB activation by TNFK through the TNF receptor interacting
protein- and TNF receptor-associated factor-2 (TRAF-2)-
mediated signaling events inhibits the apoptotic pathways.
Thus, although capable of inducing both pro-apoptotic and
pro-in£ammatory signaling pathways, TNF probably cannot
activate both these processes simultaneously and may not be
the pathologically relevant factor of sepsis, as suggested by
the recent failure of TNF-directed therapies [64,82].
6. Conclusion
In summary, the simultaneous occurrence of in£ammation
and apoptosis is an important pathogenic event in septic
shock and their inhibition may provide useful therapies for
treatment of sepsis. In agreement, inhibition of pro-in£amma-
tory cytokine synthesis as well as T cell apoptosis by C5a
blockade protects mice from CLP-induced mortality. Further
extension of our studies with the lethal and non-lethal
immune responses to LPS will help con¢rm the role(s)
of C5a, caspases, MAP kinases and IFNK/L-stimulated sig-
naling events in in£ammation and apoptosis during septic
death.
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